Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

2008 and Recent Events Highlighted

EMERYVILLE, Calif., April 1, /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, reported today its financial results for the fourth quarter and full year ended December 31, 2008. The company also announced clinical development progress and operational highlights during the year 2008.

License and collaboration revenue for the fourth quarter of 2008 increased 44% to $2.2 million from $1.5 million for the fourth quarter of 2007. The net loss for the fourth quarter of 2008 was $(1.5) million, or $(0.07) per share, compared to a net loss of $(1.4) million, or $(0.09) per share, reported for the fourth quarter of 2007. License and collaboration revenue for the year ended December 31, 2008 increased 14% to $6.7 million, from $5.9 million for the year ended December 31, 2007. The net loss for the year ended December 31, 2008 was $8.1 million, or $(0.38) per share, compared to a net loss of $5.4 million, or $(0.60) per share reported for the year ended December 31, 2007. As of December 31, 2008, the company's cash and cash equivalents totaled $12.1 million.

"During 2008, NovaBay continued to advance development of our Aganocide(R) compounds, our proprietary, first-in-class anti-infective products that are designed to mimic the human body's natural defense against infection without developing resistance," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "We have built on this solid progress in 2009, as evidenced by our recently announced exclusive agreement with Galderma to develop and commercialize our Aganocides for major dermatological conditions. This is NovaBay
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ber 30, 2009 An international team of applied sci... Zrich have demonstrated compact, multibeam, and m...art of the light spectrum (infrared). By contrast,...-defined wavelength. The innovative multibeam lase...emote chemical sensing pollution monitoring, optic...
(Date:11/30/2009)...FF MANOR, N.Y., Nov. 30 Good Publi...for the publication of company-sponsored medical r...itish Medical Journal (BMJ). "The publication of G... of providing support and guidance for industry sp...lts in the peer-reviewed medical literature," said...
(Date:11/30/2009)... Nov. 30 BioMarin Pharma...t the Food and Drug Administration (FDA) has grant... (3,4-DAP), amifampridine phosphate, for the rare ...me (LEMS). 3,4-DAP has previously received orphan...09, the Committee for Medicinal Products for Human...
(Date:11/30/2009)...ONDON, November 30 ApaTech, the ra...rope,s fastest growing,Biotech/Pharmaceutical/Medi...009 Technology Fast 500 for EMEA (Europe, Middle E... based on a companies, five-year revenue growth,f...r this period. This,achievement places ApaTech 9th...
Breaking Biology Technology:Scientists demonstrate multibeam, multi-functional lasers 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4
... 30 Occlutech GmbH, the leading,European manufact... that it,has won its litigation case in The Hague,...nfringement of the Dutch version of the European p... stated that the disputed Occlutech,products do no...nt of,German patent DE 695 34 505.2) held by AGA M...
... David B. Samadi, M.D., a world renowned urolo... surgery techniques, following an OR Live Webcast.... and organs responsible for sexual function and co...,500 robotic prostate surgeries and the results ar... New York, NY (PRWEB) October 30, 2008 ...
... The latest software release for the V and Vma...mmunication options for individuals who cannot spe...ning disabilities, ease device setup and use, and ...ications outside the V/Vmax communication software...tober 30, 2008 -- DynaVox, the world,s leading p...
Other Biology Technology:Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical 2Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 2Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 3Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 4DynaVox Releases Software Version 1.05 for DynaVox V and Vmax 2DynaVox Releases Software Version 1.05 for DynaVox V and Vmax 3
(Date:11/30/2009)...o rise scientists are presented with the complex c...adapt. In a paper published in Insect Conservatio...nd Dr Miguel Rodriguez assess this challenge. , ...0.6˚C has already affected the Earth,s biota ...evolutionary biologists is to predict how biologic...
(Date:11/30/2009)... seeing your extended family over the holidays was... in the December 2009 print issue of the Journal ...shows that you might be right. Here,s the good new...ely new treatments that help keep autoimmune disea...l. That,s because researchers from the University ...
(Date:11/30/2009)...ss radioactive gas that is produced by the radioac...um decay and is found in trace amounts naturally i... as building materials, plants, animals, and the h...s the amount of radiation that would be emitted by...hus the units are picocuries per liter (pCi/L). Th...
Breaking Biology News(10 mins):How can scientists measure evolutionary responses to climate change? 2Seeing family for the holidays? Scientists discover how the stress might kill you 2Health Physics Society recommends considering action for indoor radon below current guidelines 2Lethality of H1N1 Virus Drops to 26quot 3BNon Epidemic Resting Levels 26quot 3B in Current Cycle 3B Virus 26apos 3B Infectivity Remains Increased 62195 1Lethality of H1N1 Virus Drops to 26quot 3BNon Epidemic Resting Levels 26quot 3B in Current Cycle 3B Virus 26apos 3B Infectivity Remains Increased 62195 2Lethality of H1N1 Virus Drops to 26quot 3BNon Epidemic Resting Levels 26quot 3B in Current Cycle 3B Virus 26apos 3B Infectivity Remains Increased 62195 3Lethality of H1N1 Virus Drops to 26quot 3BNon Epidemic Resting Levels 26quot 3B in Current Cycle 3B Virus 26apos 3B Infectivity Remains Increased 62195 4Lethality of H1N1 Virus Drops to 26quot 3BNon Epidemic Resting Levels 26quot 3B in Current Cycle 3B Virus 26apos 3B Infectivity Remains Increased 62195 5Varian Medical Systems to Highlight the Latest Digital Detectors X ray Tubes and Cancer Treatment Technology at the Radiological Society of North Ame 6555 1Varian Medical Systems to Highlight the Latest Digital Detectors X ray Tubes and Cancer Treatment Technology at the Radiological Society of North Ame 6555 2Shamir Optical Industry Ltd Announces Declaration of a Cash Dividend 62190 1Shamir Optical Industry Ltd Announces Declaration of a Cash Dividend 62190 2
...Improvements to the technology infrastructure for ...would be expected to save the industry hundreds of...economic study* sponsored by the National Institut...by RTI International for NIST, the studys authors ...ew drug development has shifted from small-molecul...
...A modified plastic material greatly improves the a...oxide from natural gas as the gas is prepared for ...exas at Austin who have analyzed the new plastics ...ertain chemicals, the new plastic permits carbon d...-glass shaped pores within it, while impeding natu...
...iophysicists at the University of Pennsylvania hav...re particularly soft and flexible, rather than har...ugh the body and to adopt different shapes, but ul... sector for proper access and expression. ,Researc...es under controlled pressures and visualized the s...
Other Biology News:Biopharmaceutical infrastructure key to lower drug development costs 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3Stem cell nuclei are soft 'hard drives,' Penn study finds 2
Corning Culture Flask, 75 cm2, Tc-Treated, Straight Neck, Phenolic-Style Cap, Sterile from Sigma-Aldrich
Buffer for sal I 10X (do not list in catalog) BLACK (Sal I) from Sigma-Aldrich
Taq DNA Polymerase from ABgene
...the Adept CE 4100 high pressure dual piston pump a...tector for added flexibility and utra low drift. ...to a photodiode array detection and provides super...ed for method development and for monitoring to th...
Biology Products: